SCHEMBL3483777

SCHEMBL3483777

Cc1ccc2sc(S(=O)(=O)NC(=O)O)cc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.60
AKR1B1 P15121 1/20 0.47
F10 P00742 1/20 0.47
PFKFB4 Q16877 1/20 0.46
KIT P10721 1/20 0.44
CYP2A6 P11509 1/20 0.44
CA2 P00918 6/20 0.42
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 2/20 0.39
DYRK1A Q13627 1/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8231606 0.84 FBP1 (0.53) FBP1AKR1B1F10PFKFB4KIT
SCHEMBL3063018 0.79 AKR1B1 (0.52) FBP1AKR1B1F10PFKFB4KIT
SCHEMBL5188556 0.79 FLT1 (0.61) FBP1
SCHEMBL788574 0.77 PFKFB4 (0.60) PFKFB4KITMEN1KMT2AALDH1A1
SCHEMBL2176140 0.76 FBP1 (1.00) FBP1
SCHEMBL9997190 0.76 ALDH1A1 (0.54) FBP1PFKFB4KITMEN1MAPT
SCHEMBL2088019 0.76 CA2 (0.65) AKR1B1CYP2A6CA2
SCHEMBL787824 0.76 AKR1B1 (0.52) FBP1AKR1B1F10PFKFB4KIT
SCHEMBL2087977 0.75 FBP1 (0.61) FBP1CA2MAPTALDH1A1FLT3
SCHEMBL2801905 0.70 BCL2L1 (0.59) CYP2A6MEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS FBP1 234/4885AKR1B1 3286/4885F10 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.